Therapeutic proteins are commonly conjugated with polymers to modulate their pharmacokinetics but often lack a description of the polymer-protein interaction. We deployed limited proteolysis mass spectrometry (LiP-MS) to reveal the interaction of polyethylene glycol (PEG) and PEG alternative polymers with interferon-α2a (IFN). Target conjugates were digested with the specific protease trypsin and a "heavy" N-IFN wild type (IFN-WT) for time-resolved quantification of the cleavage dynamics. Interactions between IFN-α2a and its high-affinity receptor were detailed by LiP-MS. Then, 10 kDa polymers of PEG, linear polyglycerol (LPG), and poly(2-oxazoline) (POX) with two different cyclooctyne linkers (BCN/DBCO) were used for site-specific bioconjugation to azide functionalized IFN-α2a. Tryptic events at each cleavage site and in different structural environments (loops/helices) were compared. PEG and LPG were similar, and POX showed a reduced interaction profile with the IFN-α2a surface. All-atom molecular dynamics simulations of IFN-DBCO-polymer conjugates revealed distinct and transient (below 50 ns) protein-interaction profiles for PEG, LPG, and POX. Cleavage dynamics of IFN-polymer conjugates from the BCN handle were homogeneous, pointing to a more conserved IFN structure than DBCO-polymer conjugates. In summary, time-resolved LiP-MS for quantification of cleavage events enhances the structural understanding of transient IFN-polymer interactions, which may be extended to other bioconjugate types.

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.202415354DOI Listing

Publication Analysis

Top Keywords

limited proteolysis
8
proteolysis mass
8
mass spectrometry
8
quantification cleavage
8
cleavage dynamics
8
peg lpg
8
lpg pox
8
peg
5
deciphering polymer
4
polymer interactions
4

Similar Publications

Inducible protein switches are currently limited for use in tissues and organisms because common inducers cannot be controlled with precision in space and time in optically dense settings. Here, we introduce a protein that can be reversibly toggled with a small change in temperature, a stimulus that is both penetrant and dynamic. This protein, called Melt (Membrane localization using temperature) oligomerizes and translocates to the plasma membrane when temperature is lowered.

View Article and Find Full Text PDF

Unleashing the Power of Covalent Drugs for Protein Degradation.

Med Res Rev

January 2025

Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.

Targeted protein degradation (TPD) has emerged as a significant therapeutic approach for a variety of diseases, including cancer. Advances in TPD techniques, such as molecular glue (MG) and lysosome-dependent strategies, have shown substantial progress since the inception of the first PROTAC in 2001. The PROTAC methodology represents the forefront of TPD technology, with ongoing evaluation in more than 20 clinical trials for the treatment of diverse medical conditions.

View Article and Find Full Text PDF

Organisms have evolved protective strategies that are geared toward limiting cellular damage and enhancing organismal survival in the face of environmental stresses, but how these protective mechanisms are coordinated remains unclear. Here, we define a requirement for neural activity in mobilizing the antioxidant defenses of the nematode both during prolonged oxidative stress and prior to its onset. We show that acetylcholine-deficient mutants are particularly vulnerable to prolonged oxidative stress.

View Article and Find Full Text PDF

Targeted protein degraders, in the form of proteolysis targeting chimaeras (PROTACs) and molecular glues, leverage the ubiquitin-proteasome system to catalytically degrade specific target proteins of interest. Because such molecules can be extremely potent, they have attracted considerable attention as a therapeutic modality in recent years. However, while targeted degraders have great potential, they are likely to face many of the same challenges as more traditional small molecules when it comes to their development as therapeutics.

View Article and Find Full Text PDF

Research Advances in Chaperone-Mediated Autophagy (CMA) and CMA-Based Protein Degraders.

J Med Chem

January 2025

Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu 610041, China.

Molecular mechanisms of chaperone-mediated autophagy (CMA) constitute essential regulatory elements in cellular homeostasis, encompassing protein quality control, metabolic regulation, cellular signaling cascades, and immunological functions. Perturbations in CMA functionality have been causally associated with various pathological conditions, including neurodegenerative pathologies and neoplastic diseases. Recent advances in targeted protein degradation (TPD) methodologies have demonstrated that engineered degraders incorporating KFERQ-like motifs can facilitate lysosomal translocation and subsequent proteolysis of noncanonical substrates, offering novel therapeutic interventions for both oncological and neurodegenerative disorders.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!